Presentation is loading. Please wait.

Presentation is loading. Please wait.

Armodafinil for Sarcoidosis-Associated Fatigue: A Double-Blind, Placebo-Controlled, Crossover Trial  Elyse E. Lower, MD, Atul Malhotra, MD, Victoria Surdulescu,

Published byΕυγένεια Κουταλιανός Modified over 5 years ago

Similar presentations

Presentation on theme: "Armodafinil for Sarcoidosis-Associated Fatigue: A Double-Blind, Placebo-Controlled, Crossover Trial  Elyse E. Lower, MD, Atul Malhotra, MD, Victoria Surdulescu,"— Presentation transcript:

1 Armodafinil for Sarcoidosis-Associated Fatigue: A Double-Blind, Placebo-Controlled, Crossover Trial 
Elyse E. Lower, MD, Atul Malhotra, MD, Victoria Surdulescu, MD, Robert P. Baughman, MD  Journal of Pain and Symptom Management  Volume 45, Issue 2, Pages (February 2013) DOI: /j.jpainsymman Copyright © 2013 U.S. Cancer Pain Relief Committee Terms and Conditions

2 Fig. 1 Flow diagram summarizing the double-blind, placebo-controlled, crossover design of the study. Overnight sleep studies followed by multiple sleep latency tests (MSLT) were performed prior to randomization and at the end of each eight-week treatment period. Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman ) Copyright © 2013 U.S. Cancer Pain Relief Committee Terms and Conditions

3 Fig. 2 CONSORT diagram22 detailing the outcome of studied patients. Ten patients were unable or unwilling to undergo an initial sleep study. After the initial sleep study, five patients were excluded from further study because of inadequately controlled sleep apnea or restless leg syndrome. Fourteen patients completed all 19 weeks of the study as detailed in Fig. 1. Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman ) Copyright © 2013 U.S. Cancer Pain Relief Committee Terms and Conditions

4 Fig. 3 The change of the Fatigue Assessment Scale (FAS) score after four or eight week of therapy compared with the baseline value (Week 1 or 11). There was a significant difference between armodafinil and placebo after eight weeks of therapy (P=0.0295). Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman ) Copyright © 2013 U.S. Cancer Pain Relief Committee Terms and Conditions

5 Fig. 4 The change of the Functional Assessment of Chronic Illness Therapy—Fatigue (FACIT-F) score after four or eight week of therapy compared with the baseline value (Week 1 or 11). There was a significant difference between armodafinil and placebo after four and eight weeks of therapy (P= and P=0.0040, respectively). Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman ) Copyright © 2013 U.S. Cancer Pain Relief Committee Terms and Conditions

Download ppt "Armodafinil for Sarcoidosis-Associated Fatigue: A Double-Blind, Placebo-Controlled, Crossover Trial  Elyse E. Lower, MD, Atul Malhotra, MD, Victoria Surdulescu,"

Similar presentations

Treatment of postherpetic neuralgia: a review of therapeutic options Charles E. Argoff, MD, Nathaniel Katz, MD, Miroslav Backonja, MD Journal of Pain and.

Treatment of postherpetic neuralgia: a review of therapeutic options Charles E. Argoff, MD, Nathaniel Katz, MD, Miroslav Backonja, MD Journal of Pain and.
Comparison of the Constipation Assessment Scale and Plain Abdominal Radiography in the Assessment of Constipation in Advanced Cancer Patients Kittiphon.

Comparison of the Constipation Assessment Scale and Plain Abdominal Radiography in the Assessment of Constipation in Advanced Cancer Patients Kittiphon.
Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study  Uwe Kern, MD, Bernd Altkemper,

Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study  Uwe Kern, MD, Bernd Altkemper,
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain  Xiaowei.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain  Xiaowei.
Christine Miaskowski, RN, PhD, FAAN, Steven M. Paul, PhD, Bruce A

Christine Miaskowski, RN, PhD, FAAN, Steven M. Paul, PhD, Bruce A
One-Year rTMS Treatment for Refractory Trigeminal Neuralgia

One-Year rTMS Treatment for Refractory Trigeminal Neuralgia
Chronic Pain Management in Older Adults: Special Considerations

Chronic Pain Management in Older Adults: Special Considerations
Managing Metastatic Bone Pain: The Role of Bisphosphonates

Managing Metastatic Bone Pain: The Role of Bisphosphonates
Patient-Reported Outcomes as a Component of the Primary Endpoint in a Double-Blind, Placebo-Controlled Trial in Advanced Pancreatic Cancer  S. Gail Eckhardt,

Patient-Reported Outcomes as a Component of the Primary Endpoint in a Double-Blind, Placebo-Controlled Trial in Advanced Pancreatic Cancer  S. Gail Eckhardt,
Carmelita P. Escalante, MD, Michael A. Kallen, PhD, MPH, Rosalie U

Carmelita P. Escalante, MD, Michael A. Kallen, PhD, MPH, Rosalie U
Clinical Trial Results with OROS® Hydromorphone

Clinical Trial Results with OROS® Hydromorphone
Managing Metastatic Bone Pain: The Role of Bisphosphonates

Managing Metastatic Bone Pain: The Role of Bisphosphonates
Wen Jing Chung, MD, MS, Gregory H. Pharo, DO 

Wen Jing Chung, MD, MS, Gregory H. Pharo, DO 
A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain  Richard L. Rauck, MD, Mark S. Wallace,

A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain  Richard L. Rauck, MD, Mark S. Wallace,
An Effective Treatment of Severe Complex Regional Pain Syndrome Type 1 in a Child Using High Doses of Intrathecal Ziconotide  Michael Stanton-Hicks, MD,

An Effective Treatment of Severe Complex Regional Pain Syndrome Type 1 in a Child Using High Doses of Intrathecal Ziconotide  Michael Stanton-Hicks, MD,
Chronic Pain Management in Older Adults: Special Considerations

Chronic Pain Management in Older Adults: Special Considerations
A Case Series of Patients Using Medicinal Marihuana for Management of Chronic Pain Under the Canadian Marihuana Medical Access Regulations  Mary E. Lynch,

A Case Series of Patients Using Medicinal Marihuana for Management of Chronic Pain Under the Canadian Marihuana Medical Access Regulations  Mary E. Lynch,
Opioids for Cancer Breakthrough Pain: A Pilot Study Reporting Patient Assessment of Time to Meaningful Pain Relief  Giovambattista Zeppetella, FRCP  Journal.

Opioids for Cancer Breakthrough Pain: A Pilot Study Reporting Patient Assessment of Time to Meaningful Pain Relief  Giovambattista Zeppetella, FRCP  Journal.
Long-Term Opioid Therapy for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis of Efficacy and Safety  Meredith Noble, MS, Stephen J. Tregear,

Long-Term Opioid Therapy for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis of Efficacy and Safety  Meredith Noble, MS, Stephen J. Tregear,
Analgesic and Sedative Effects of Melatonin in Temporomandibular Disorders: A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study  Liliane.

Analgesic and Sedative Effects of Melatonin in Temporomandibular Disorders: A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study  Liliane.

Similar presentations

Ads by Google